Regulatory Guidance Monthly Review - June 2023
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
Posts about
Regulatory Submissions (8)
How does Real-World Evidence Impact Medicinal Product Development in Europe?
Explore the growing role of Real-World Evidence (RWE) in the regulatory decision-making process...
Regulatory Guidance Monthly Review - May 2023
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
Regulatory Guidance Monthly Review - April 2023
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
Regulatory Guidance Monthly Review - March 2023
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
Bold Thinking that Delivers Results for RNA Therapies
Current advances in RNA-based therapies hold substantial promise in treating and preventing many...
Regulatory Guidance Monthly Review - February 2023
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
European Medicines and Medical Devices: Future Trends
Based on an online seminar presentation made in collaboration with TOPRA and Veristat, this article...
Podcast: Orphan Drug Designations and Orphan Subsets
Sponsors developing drugs or biologics intended to prevent, diagnose, or treat a rare disease or...
Regulatory Guidance Monthly Review - January 2023
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...